A Diagnostic Odyssey in a Family with Multiple Osteochondromas

Read full text Summarise with VIRAT
Authors: Yan Xu, Niu Li, Jian Wang, Yan Wang, Shuyuan Li
Cited by: 0
References: 11

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

What additional steps should be taken when a patient has a clinical diagnosis suggestive of hereditary multiple osteochondromas (HMO) but initial genetic testing is negative? What are the limitations of exome sequencing (ES) and multiplex ligation-dependent probe amplification (MLPA) in detecting partial-exon deletion? Which genetic testing approaches are most effective for detecting partial-exon deletions? How should clinicians reconcile discordance between strong clinical suspicion and negative genetic results? A 28-year-old man presenting with multiple osteochondromas was referred to our institution for genetic counseling regarding reproductive risks. The proband (III-12) reported a striking familial history spanning multiple generations, with at least 19 individuals in the extended pedigree suspected to be affected (Fig. 1A). Physical examination revealed numerous bony exostoses primarily affecting the elbows, knees, and ankles (Fig. 1B, top). He had a history of several orthopedic interventions to correct joint deformities and improve mobility (Fig. 1B, bottom). Clinical and molecular findings in a family with multiple osteochondromas. (A), Pedigree of the four-generation family. The proband (III-12) is marked by an arrow. Filled symbols denote affected individuals; open symbols denote unaffected individuals. Asterisks indicate individuals who underwent genetic testing. (B), Clinical images of the proband showing osteochondromas at the elbow and ankle (upper panel) and postoperative changes of the knee and thigh (lower panel). (C), Integrative Genomics Viewer (IGV) visualization of whole-genome sequencing reads at the EXT2 locus, with arrows indicating the identified deletion breakpoints. (D), Long-range PCR and Sanger sequencing confirming a heterozygous deletion spanning part of exon 2 and intron 2, with a 5-bp insertion at the junction. Long-range PCR primers: 5′-ATCACCCTCTTCTCCATTGTC-3′ (forward) and 5′-GTCCCATACAGACCTGCTTCTA-3′ (reverse). (E), Quantitative real-time PCR analysis demonstrating reduced copy number for 2 primer pairs located within the deleted region: del primer 1 (forward-5′-GGGAATGCTTCTGCTCTTGAGTT-3′ and reverse-5′-TGTAAGTGCTACGAGGAGGTGGT-3′) and del primer 2 (forward- 5′-TCTCACACTCATACAGCCCA-3′ and reverse-5′-AGCAGAAGCATTCCCATCCT-3′). One pair of primers (forward-5′-GTGACCAGGAGTGTGAGGAAGA-3′ and reverse-5′-AGGAGGACAATGGAGAAGAGGG-3′) was used to detect the normal region without deletion. (F), Reverse transcription PCR and cDNA sequencing showing an aberrant transcript lacking exon 2. Primers sequences were as follows: 5′-CCGATCCGACCTGGGCGGAG-3′ (forward) and 5′-GGAAGTATTGCCGTGGACCTG-3′ (reverse). P: proband; B: brother of the proband; Fa: father; Mo: mother; Ctrl: control; M: marker. Proband-only ES was initially performed on an MGISEQ-2000 platform at the Beijing Genomics Institute (BGI, Shenzhen, China). However, no pathogenic variants were identified. Given that copy number variations (CNVs) in exostosin-1 (EXT1, HGNC: 3512, 8q24.11, OMIM number: 608177) or exostosin-2 (EXT2, HGNC:3513, 11p11.2, OMIM number: 608210) represent a small but significant proportion (4% to 9%) of cases with hereditary multiple osteochondromas (HMO, OMIM number: 133700), multiplex ligation-dependent probe amplification (MLPA) was conducted; however, no intragenic CNVs were detected. To further resolve the genetic basis, trio-based ES, including both parents, was performed; however, this analysis also failed to identify a detectable causative variant. To resolve the diagnostic odyssey, research-based trio whole-genome sequencing (WGS) was performed using a DNBSEQ-T7 platform at the BGI. Variant calling for single-nucleotide variants (SNVs) and small insertions/deletions (indels, 10%. Moreover, the functional significance of the exon 2 region is underscored by documented pathogenic variants upstream of this putative ATG in affected individuals, including similar exon 2 deletions (2, 3). According to the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) guidelines (4), it is classified as likely pathogenic (PVS1_Strong + PM2_Supporting + PP1 + PP4). Collectively, the combined evidence strongly supports that this heterozygous deletion is the disease-causing variant in this family. The proband’s clinical features—multiple osteochondromas involving long bones and a clear autosomal dominant pattern across 4 generations (Fig. 1A)—was highly suggestive of HMO, also known as hereditary multiple exostoses (HME). HMO is an autosomal dominant skeletal disorder characterized by the development of multiple osteochondromas, which are benign cartilage-capped bone tumors growing outward from the metaphyses of long tubular bones. Although osteochondromas may occur throughout the skeleton, they most frequently involve the distal femur, proximal tibia, fibula, and humerus (2). Associated complications include skeletal deformities, limb-length discrepancy, fractures, bursitis, and neurovascular compression (5). Clinical diagnosis is typically based on radiographic identification of more than 2 osteochondromas; however, molecular confirmation is essential for accurate genetic counseling and reproductive risk assessment. HMO is genetically heterogeneous, with approximately 70% to 95% of cases attributable to pathogenic variants in EXT1 or EXT2 (6). The majority (about 80%) of reported variants are nonsense, frameshift, and splice-site variants resulting in loss of EXT1/EXT2 function (2). Missense variants account for around 10% of cases, whereas single- or multi-exon deletions/duplications in EXT1 or EXT2 contribute an additional 4% to 9% (2). Notably, 10% to 15% of clinically diagnosed HMO cases remain genetically unresolved. Possible explanations include cryptic alterations that are not detectable by the conventional method, such as deep intronic or regulatory variants, structural rearrangements (e.g., inversions), somatic mosaicism, or involvement of yet-to-be-identified genes (7, 8). Recommended diagnostic evaluation therefore includes both sequence analysis and CNV/SV analysis of EXT1 and EXT2. In this case, ES was initially performed because of its high diagnostic yield for monogenic disorders, but no pathogenic variants were identified. Although manual inspection of BAM files suggested decreased read depth at the terminal region of EXT2 exon 2 (Fig. 2A), this potential signal was not captured by the ES analysis pipeline. This discrepancy highlights a recognized limitation of current ES-based analysis work flows—despite advances in computational tools, the detection of small or complex SVs from ES data remains technically challenging and often requires specialized algorithms and expertise. Schematic of the identified deletion in the family. (A), Integrative Genomics Viewer view of exome sequencing reads aligned to EXT2. The corresponding exome breakpoint boundaries according to the WGS result were indicated by arrows. (B), Diagram of the 895 bp deletion in EXT2 detected by whole-genome sequencing. The deletion spans part of exon 2 and intron 2, as indicated by the line with endpoints at both ends. MLPA probes flanking the region (boxes) and qPCR primer sets used for validation (arrows) are indicated. MLPA, multiplex ligation-dependent probe amplification; qPCR, quantitative real-time PCR; WGS: whole-genome sequencing; del: deletion; F/R: forward or reverse primer. To further evaluate the possibility of a CNV, MLPA targeting EXT1 and EXT2 was performed. While chromosomal microarray analysis (CMA) is a robust tool for genome-wide CNV detection, MLPA is the first-line method for detecting single- or multi-exon deletions/duplications within these specific loci (2). However, no abnormalities were detected. Closer examination of the kit's probe design revealed that the 895 bp deletion was located in a gap region between 2 probes targeting EXT2 exon 2 and exon 3, respectively (Fig. 2B). Specifically, the exon 2 probe (07466-L06431) was located 33 bp upstream of the 5′ breakpoint, whereas the exon 3 probe (06838-L06432) was situated 351 bp downstream of the 3′ breakpoint. This case perfectly illustrates a critical limitation of MLPA assays: small or partially overlapping deletions outside predefined target regions may escape detection. Exon 2 of EXT2 is a recognized mutational hotspot, accounting for approximately 30% of all reported variants in this gene (9). Most previously described exon 2 variants are sequence-level variants, including nonsense, frameshift, small indels, or missense changes. In contrast, single-exon deletion involving exon 2 are uncommon, with only 2 recorded in ClinVar (as of January 9, 2026). Intragenic deletions that span exon–intron boundaries are particularly rare. Reported examples include a 422-bp deletion (c.-30-10_441del) with one of the breakpoints confirmed to be in exon 2 using long-range PCR and Sanger sequencing (10), and a partial intron 4/exon 5 deletion reported by Corsini et al., although its breakpoints remained unresolved (11). In this study, we identified a previously unreported 895 bp deletion encompassing part of EXT2 exon 2 and the flanking intronic regions using WGS. The deletion was confirmed by qPCR, long-range PCR, and Sanger sequencing, and its functional impact was confirmed by RNA studies demonstrating exon-2 skipping and production of an aberrant transcript. To our knowledge, this is the first report of a heterozygous deletion-type SV involving partial EXT2 exon 2 and flanking intronic regions defined at nucleotide resolution using WGS. In conclusion, this case highlights the diagnostic challenges in detecting small intragenic deletion-type SVs using MLPA or ES-based bioinformatic work flows. This finding emphasizes the added value of WGS in cases with strong clinical suspicion but negative prior testing. Comprehensive genomic approaches—supported by orthogonal validation such as qPCR, long-range PCR, and RNA analysis—remain essential for resolving challenging Mendelian disorders such as HMO. A negative molecular result in a clinically suspected HMO patient should prompt consideration of variants not detectable by standard methods, such as deep intronic, regulatory, or complex structural variants. Patients with a positive family history may harbor structural variants; although rare, variants of this type in EXT1 or EXT2 have been reported and should be considered in unresolved cases. WGS offers superior sensitivity for intragenic structural rearrangements because it provides uniform, genome-wide coverage, whereas targeted methods such as ES and MLPA—designed to detect predefined sequences or dosage changes—may fail to identify small or complex structural variants. Nonstandard Abbreviations: HMO, hereditary multiple osteochondromas; ES, exome sequencing, MLPA, multiplex ligation-dependent probe amplification; BGI, Beijing Genomics Institute; CNV, copy number variant; WGS, whole-genome sequencing; SNV, single-nucleotide variant; SV, structural variant; qPCR, quantitative PCR; RT-PR, reverse transcription PCR; ACMG, American College of Medical Genetics and Genomics; AMP, Association for Molecular Pathology; HME; hereditary multiple exostoses. Author Contributions: The corresponding author takes full responsibility that all authors on this publication have met the following required criteria of eligibility for authorship: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; (c) final approval of the published article; and (d) agreement to be accountable for all aspects of the article thus ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved. Nobody who qualifies for authorship has been omitted from the list. Yan Xu (Formal analysis [equal], Writing—original draft [lead]), Niu Li (Formal analysis [equal]), Jian Wang (Conceptualization, Writing—review & editing [equal]), Yanlin Wang (Conceptualization, Writing—review & editing [equal]), and Shuyuan Li (Conceptualization, Writing—review & editing [lead]). Authors’ Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Research Funding: This work was supported by the National Natural Science Foundation of China (No. 8241687) and the Shanghai Municipal Science and Technology Commission (22Y11906700). Disclosures: None declared. Acknowledgments: The authors are grateful to the patient and the family for their written consent and their assistance.

Fields of Study & Subjects

Bone Tumor Diagnosis and Treatments Genomics and Rare Diseases Connective tissue disorders research

Publication details

Journal / source
The Journal of Applied Laboratory Medicine
Volume
11
Issue
5
Pages
1263–1269
Publication date
27 March 2026
Language
EN